Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
FDA Accepts LEQEMBI® IQLIK Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
FDA Accepts LEQEMBI® IQLIKTM Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® for Spinal Muscular Atrophy
Biologics License Application for Subcutaneous Formulation of "LEQEMBI®" for the Treatment of Early Alzheimer's Disease Accepted in China
The Journal of the American Medical Association Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
"LEQEMBI®" for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society Annual Meeting
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease Conference 2025
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease Conference 2025
New Data Presented at the Clinical Trials on Alzheimer's Disease Conference 2025 Confirms Pharmacological Effect of LEQEMBI® on Neurotoxic A? Protofibrils in CSF
New Data Presented at the Clinical Trials on Alzheimer's Disease Conference 2025 Confirms Pharmacological Effect of LEQEMBI® on Neurotoxic A? Protofibrils in CSF
Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIK Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions
